Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Mar;59(3):843–851. doi: 10.1128/iai.59.3.843-851.1991

Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates.

A F Verheul 1, A K Braat 1, J M Leenhouts 1, P Hoogerhout 1, J T Poolman 1, H Snippe 1, J Verhoef 1
PMCID: PMC258336  PMID: 1900063

Abstract

A method was developed for the well-defined coupling of phosphoethanolamine group (PEA)- and carboxylic acid group-containing polysaccharides and oligosaccharides to proteins without the need for extensive modification of the carbohydrate antigens. The carboxylic acid group of the terminal 2-keto-3-deoxyoctulosonic acid moiety was utilized to introduce a thiol function in meningococcal immunotype L2 and L3,7,9 lipopolysaccharide-derived oligosaccharides. The thiol group-containing oligosaccharides were subsequently coupled to bromoacetylated proteins. Immunotype L2 and L3,7,9 PEA group-containing oligosaccharide-tetanus toxoid conjugates were prepared, and their immunogenicities were studied in rabbits. Both the immunotype L2 and immunotype L3,7,9 conjugates evoked high immunoglobulin G (IgG) antibody titers after the first booster injection. These conjugates also displayed an ability to induce long-lasting IgG antibody levels which could be detected until 9 months after one booster injection at week 3. The adjuvant Quil A enhanced the immune response to all the conjugates to a minor extent, which is in contrast with reported adjuvant effects of Quil A on these types of antigens in mice. A conjugate prepared from the dephosphorylated L3,7,9 oligosaccharides evoked a significantly lower IgG response than a similar PEA-containing conjugate, and enzyme-linked immunosorbent assay inhibition studies indicated a different epitope specificity. Furthermore, antisera elicited with the complete bacteria contained antibodies directed against PEA-containing epitopes, which stresses the importance of the presence of unmodified PEA groups in meningococcal lipopolysaccharide-derived oligosaccharide-protein conjugates. The procedure developed offers an elegant solution for the specific coupling of meningococcal PEA-containing oligosaccharides to proteins and may therefore be a very useful tool in the development of a vaccine against group B meningococci.

Full text

PDF
843

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernatowicz M. S., Matsueda G. R. Preparation of peptide-protein immunogens using N-succinimidyl bromoacetate as a heterobifunctional crosslinking reagent. Anal Biochem. 1986 May 15;155(1):95–102. doi: 10.1016/0003-2697(86)90231-9. [DOI] [PubMed] [Google Scholar]
  2. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  3. Brandtzaeg P., Kierulf P., Gaustad P., Skulberg A., Bruun J. N., Halvorsen S., Sørensen E. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis. 1989 Feb;159(2):195–204. doi: 10.1093/infdis/159.2.195. [DOI] [PubMed] [Google Scholar]
  4. Carlsson J., Drevin H., Axén R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J. 1978 Sep 1;173(3):723–737. doi: 10.1042/bj1730723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cryz S. J., Jr, Lang A. B., Sadoff J. C., Germanier R., Fürer E. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect Immun. 1987 Jul;55(7):1547–1551. doi: 10.1128/iai.55.7.1547-1551.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dick W. E., Jr, Beurret M. Glycoconjugates of bacterial carbohydrate antigens. A survey and consideration of design and preparation factors. Contrib Microbiol Immunol. 1989;10:48–114. [PubMed] [Google Scholar]
  7. ELLMAN G. L. A colorimetric method for determining low concentrations of mercaptans. Arch Biochem Biophys. 1958 Apr;74(2):443–450. doi: 10.1016/0003-9861(58)90014-6. [DOI] [PubMed] [Google Scholar]
  8. Fattom A., Vann W. F., Szu S. C., Sutton A., Li X., Bryla D., Schiffman G., Robbins J. B., Schneerson R. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect Immun. 1988 Sep;56(9):2292–2298. doi: 10.1128/iai.56.9.2292-2298.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Finne J., Leinonen M., Mäkelä P. H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983 Aug 13;2(8346):355–357. doi: 10.1016/s0140-6736(83)90340-9. [DOI] [PubMed] [Google Scholar]
  10. Flebbe L. M., Braley-Mullen H. Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens. Cell Immunol. 1986 Apr 15;99(1):119–127. doi: 10.1016/0008-8749(86)90221-2. [DOI] [PubMed] [Google Scholar]
  11. Frasch C. E. Prospects for the prevention of meningococcal disease: special reference to group B. Vaccine. 1987 Mar;5(1):3–4. doi: 10.1016/0264-410x(87)90002-8. [DOI] [PubMed] [Google Scholar]
  12. Frasch C. E. Vaccines for prevention of meningococcal disease. Clin Microbiol Rev. 1989 Apr;2 (Suppl):S134–S138. doi: 10.1128/cmr.2.suppl.s134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jennings H. J., Beurret M., Gamian A., Michon F. Structure and immunochemistry of meningococcal lipopolysaccharides. Antonie Van Leeuwenhoek. 1987;53(6):519–522. doi: 10.1007/BF00415511. [DOI] [PubMed] [Google Scholar]
  14. Jennings H. J., Bhattacharjee A. K., Kenne L., Kenny C. P., Calver G. The R-type lipopolysaccharides of Neisseria meningitidis. Can J Biochem. 1980 Feb;58(2):128–136. doi: 10.1139/o80-018. [DOI] [PubMed] [Google Scholar]
  15. Jennings H. J., Lugowski C., Ashton F. E. Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis. Infect Immun. 1984 Jan;43(1):407–412. doi: 10.1128/iai.43.1.407-412.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jennings H. J., Roy R., Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol. 1986 Sep 1;137(5):1708–1713. [PubMed] [Google Scholar]
  17. Kamerling J. P., Gerwig G. J., Vliegenthart J. F., Clamp J. R. Characterization by gas-liquid chromatography-mass spectrometry and proton-magnetic-resonance spectroscopy of pertrimethylsilyl methyl glycosides obtained in the methanolysis of glycoproteins and glycopeptides. Biochem J. 1975 Dec;151(3):491–495. doi: 10.1042/bj1510491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kemp H. A., Morgan M. R. Studies on the detrimental effects of bivalent binding in a microtitration plate ELISA and possible remedies. J Immunol Methods. 1986 Nov 20;94(1-2):65–72. doi: 10.1016/0022-1759(86)90216-4. [DOI] [PubMed] [Google Scholar]
  19. Leinikki P. O., Shekarchi I., Dorsett P., Sever J. L. Enzyme-linked immunosorbent assay determination of specific rubella antibody levels in micrograms of immunoglobulin G per milliliter of serum in clinical samples. J Clin Microbiol. 1978 Oct;8(4):419–423. doi: 10.1128/jcm.8.4.419-423.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Michon F., Beurret M., Gamian A., Brisson J. R., Jennings H. J. Structure of the L5 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J Biol Chem. 1990 May 5;265(13):7243–7247. [PubMed] [Google Scholar]
  21. Morein B. Immunopotentiating complexes. Acta Trop Suppl. 1987 Jun;12:98–103. [PubMed] [Google Scholar]
  22. Oosterlaken T. A., Harmsen M., Kraaijeveld C. A., Snippe H. Blocking by anti-idiotypic antibodies of monoclonal antibody-mediated protection against lethal Semliki Forest virus in mice. Scand J Immunol. 1990 Feb;31(2):159–165. doi: 10.1111/j.1365-3083.1990.tb02755.x. [DOI] [PubMed] [Google Scholar]
  23. Oosterlaken T. A., Harmsen M., Tangerman C., Schielen P., Kraaijeveld C. A., Snippe H. A neutralization-inhibition enzyme immunoassay for anti-idiotypic antibodies that block monoclonal antibodies neutralizing Semliki Forest virus. J Immunol Methods. 1988 Dec 9;115(2):255–261. doi: 10.1016/0022-1759(88)90295-5. [DOI] [PubMed] [Google Scholar]
  24. Poolman J. T. Polysaccharides and membrane vaccines. Adv Biotechnol Processes. 1990;13:57–86. [PubMed] [Google Scholar]
  25. Staros J. V., Wright R. W., Swingle D. M. Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. Anal Biochem. 1986 Jul;156(1):220–222. doi: 10.1016/0003-2697(86)90176-4. [DOI] [PubMed] [Google Scholar]
  26. Svenson S. B., Lindberg A. A. Coupling of acid labile Salmonella specific oligosaccharides to macromolecular carriers. J Immunol Methods. 1979;25(4):323–335. doi: 10.1016/0022-1759(79)90025-5. [DOI] [PubMed] [Google Scholar]
  27. Trudel M., Nadon F., Seguin C., Boulay G., Lussier G. Vaccination of rabbits with a bovine herpesvirus type 1 subunit vaccine: adjuvant effect of ISCOMs. Vaccine. 1987 Sep;5(3):239–243. doi: 10.1016/0264-410x(87)90108-3. [DOI] [PubMed] [Google Scholar]
  28. Verheul A. F., Versteeg A. A., De Reuver M. J., Jansze M., Snippe H. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect Immun. 1989 Apr;57(4):1078–1083. doi: 10.1128/iai.57.4.1078-1083.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Verheul A. F., Versteeg A. A., Westerdaal N. A., Van Dam G. J., Jansze M., Snippe H. Measurement of the humoral immune response against Streptococcus pneumoniae type 14-derived antigens by an ELISA and ELISPOT assay based on biotin-avidin technology. J Immunol Methods. 1990 Jan 24;126(1):79–87. doi: 10.1016/0022-1759(90)90014-m. [DOI] [PubMed] [Google Scholar]
  30. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979 May;63(5):836–848. doi: 10.1172/JCI109383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. van Dam G. J., Verheul A. F., Zigterman G. J., de Reuver M. J., Snippe H. Estimation of the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 by inhibition ELISA. Mol Immunol. 1989 Mar;26(3):269–274. doi: 10.1016/0161-5890(89)90080-1. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES